Next generation sequencing-based MSI scoring predict benefit in dMMR tumors treated with nivolumab
María Natalia Gandur Quiroga shared a post on X:
“NGS-Based MSI Scoring Predicts Nivolumab Benefit in dMMR Tumors.
Key finding: High MSI scores (MANTIS/MSIsensor-pro) predict clinical benefit from nivolumab in mismatch repair-deficient (dMMR) tumors.
Survival: Higher TIS-RNAseq scores correlate with improved progression-free survival (HR=0.32; p=0.02).
Tumor Biology: Gene pathways (interferon and PI3K-AKT-mTOR signaling) are enriched in responders; Hedgehog signaling in non-responders.
Implication: Refines patient selection for immune checkpoint inhibitors in dMMR tumors.
Authors: Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa F. Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O’Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay Harris.”
María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies.
Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023